🔄 TRT Monitoring

What this panel can settle, and by what logic

This is not a check-up. It is the safety contract of an indefinite therapy, and its nine markers sort by consequence rather than by organ.

1. Hematocrit on the Complete Blood Count (CBC) with Differential is the number most likely to end your protocol. In a large cohort on testosterone, hematocrit passed 0.50 L/L in 11%, 0.52 L/L in 3.7% and 0.54 L/L in 0.5% Madsen 2021, and it is managed against the change from your own baseline rather than a population interval Basheer 2025.
2. PSA (Total + Free + % Free) is here for velocity, not for a threshold. A rise from 0.8 to 1.9 ng/mL across 24 months is a different clinical object from a man who has always sat at 1.9 ng/mL, and monitoring guidance is written around the change Basheer 2025 Hackett 2023.
3. Total Testosterone with SHBG (Sex Hormone-Binding Globulin) and Estradiol, Sensitive (LC/MS-MS) is what makes the dose readable. Free testosterone is derived from the total and SHBG, and the testosterone-to-estradiol ratio means nothing unless the estradiol came off a sensitive assay Swislocki 2024 Rosner 2013.
4. ApoB (Apolipoprotein B) beside the Lipid Panel (Cholesterol, HDL, LDL, Triglycerides) catches the collateral drift. Testosterone commonly lowers HDL, and ApoB reflected residual risk better than LDL cholesterol across 13,015 statin-treated adults over a median of 8 years Johannesen 2021.

What it cannot settle, and what would

Nothing on it measures whether you feel better, which is the only outcome the therapy exists for. No concentration here corresponds to symptom response: testosterone deficiency is defined as symptoms plus a repeatedly low morning level, and treatment is judged the same way Hackett 2023. A total testosterone of 850 ng/dL with no change at 6 months is a reason to reconsider the diagnosis, not to raise the dose.

It cannot compare a peak to a trough, and most men do it by accident. Short-acting esters such as cypionate and enanthate produce meaningful serum swings across a dosing cycle, and that variation complicates laboratory interpretation and safety monitoring directly Farzam 2026. A draw 2 days after an injection read against a trough from 6 months ago invents a rise that never happened, and the usual response — a dose cut, or an aromatase inhibitor — is a real intervention taken for an artifact.

It cannot tell you why the hematocrit is climbing. The rise is dose-related and it is also driven by untreated sleep apnea, and no marker on this list separates the two Platon 2023. The answers differ: dose and injection frequency Farzam 2026, or a sleep study.

And it says nothing about fertility. Exogenous testosterone suppresses the gonadotropins and with them spermatogenesis, with recovery after stopping running from months to years and no reliable predictor Desai 2022. This panel does not carry LH & FSH at all, because on therapy it is suppressed by design. The test is a semen analysis.

Draw conditions that decide whether the money is wasted

One condition dominates this page: every number here is a comparison, so the draw has to be identical every single time.

1. Trough — immediately before the next dose — morning, fasted, forever. Peak-to-trough variation on a short-acting ester is large enough to change interpretation on its own Farzam 2026, so a trend built out of mixed timings is not a trend.
2. Record the ester, dose, concentration, route, injection interval, the time of the last injection and the time of the draw. That list is what the pharmacokinetic review asks clinicians to document, and without it a result cannot be interpreted at all Farzam 2026.
3. Sensitive estradiol only. The standard immunoassay is built for female-range concentrations and is unreliable at male ones Rosner 2013, and the ratio men manage their dose by is only defined for the sensitive method Swislocki 2024.
4. Hydrated. Hematocrit is a ratio, so a dehydrated morning draw reads high — worth knowing before a genuine dose change is made on the back of it Basheer 2025.
5. No hard training for 48 hours, nothing biotin-containing for 3 days, and not within 2 weeks of an illness. Training moves the Comprehensive Metabolic Panel (CMP) enzymes and creatinine, illness moves hs-CRP (High-Sensitivity C-Reactive Protein) and the Complete Blood Count (CBC) with Differential differential, and biotin at 5,000 mcg and above moves anything streptavidin-based Li 2020. On a 9-marker safety panel that is 3 of the 9 in play at once.

How you would know it answered your question, and what each pattern means next

The cadence is 6 to 8 weeks after any dose change, then every 6 to 12 months once stable Hackett 2023. The 6 to 8 weeks is not a round number: it is roughly how long a short-acting ester takes to settle to a stable trough after a change, so a 3-week recheck is measuring the transition Farzam 2026.

• Hematocrit above 0.52 L/L: change the protocol before reaching for routine donation, which trades erythrocytosis for iron deficiency and its own fatigue. Dose, injection frequency and a sleep apnea assessment come first Madsen 2021 Basheer 2025. Recheck the Complete Blood Count (CBC) with Differential 8 to 12 weeks after any change, which is the span over which red cell mass re-equilibrates.
• PSA (Total + Free + % Free) up by more than about 1 ng/mL in 12 months, or above 4 ng/mL: urology, before the next dose adjustment Basheer 2025 Hackett 2023.
• Symptoms cycling within the week on a stable weekly dose: the problem is distribution, not total dose. Smaller and more frequent injections are the first move; a dose increase is not Farzam 2026.
• Estradiol, Sensitive (LC/MS-MS) high with no symptoms: leave it. Crashed estradiol produces joint pain, low libido and low mood, and the ratio is read against how you feel rather than driven down on principle Swislocki 2024.
• ApoB (Apolipoprotein B) risen from your pre-treatment value: that is the collateral this panel exists to catch, and it is treatable independently of the testosterone Johannesen 2021.

Sources read for these sections

• Madsen MC, et al. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years. Journal of Clinical Endocrinology and Metabolism 2021 · PMID 33599731
• Basheer B, et al. Management of Adverse Effects in Testosterone Replacement Therapy. International Braz J Urol 2025 · PMID 39908204
• Hackett G, et al. The British Society for Sexual Medicine Guidelines on Male Adult Testosterone Deficiency, with Statements for Practice. World Journal of Men's Health 2023 · PMID 36876744
• Farzam K. Individualizing Injectable Testosterone Replacement Therapy in Primary Care: Pharmacokinetics, Symptom Stability, Safety Monitoring, and Injection Frequency. Cureus 2026 · PMID 42292725
• Swislocki ALM, et al. A Review on Testosterone: Estradiol Ratio-Does It Matter, How Do You Measure It, and Can You Optimize It?. World Journal of Men's Health 2024 · PMID 39344113
• Rosner W, et al. Challenges to the measurement of estradiol: an endocrine society position statement. Journal of Clinical Endocrinology and Metabolism 2013 · PMID 23463657
• Johannesen CDL, et al. Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. Journal of the American College of Cardiology 2021 · PMID 33736827
• Platon AL, et al. An Update on Obstructive Sleep Apnea Syndrome-A Literature Review. Medicina (Kaunas) 2023 · PMID 37629749
• Desai A, et al. Understanding and managing the suppression of spermatogenesis caused by testosterone replacement therapy (TRT) and anabolic-androgenic steroids (AAS). Therapeutic Advances in Urology 2022 · PMID 35783920
• Li D, Ferguson A, Cervinski MA, Lynch KL, Kyle PB. AACC Guidance Document on Biotin Interference in Laboratory Tests. J Appl Lab Med 2020 · PMID 32445355